EN DE
Watch NeoGenomics Inc for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

NeoGenomics Inc (NEO) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of NeoGenomics Inc stock $13.28, price $15.25, that is 12.9% below the price, quality 44 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US64049M2098

NI NeoGenomics Inc logo Thin data Nov 17, 2026

NeoGenomics Inc

NEO · US

Expensive (fair value 13% below the price) and weak company, but rising price: meets 1 of 3 rules.

Follow free in the weekly email
Rising price (uptrend) 
Low debt 
Profit last quarter +131% vs. a year ago. 
Quality 44/100 
Mixed Growth (revenue 5y +10.4 %/yr in USD) 
Insiders sold $440,224 (6M) 
Fair value $13.28 · Overvalued 
Loss-making · -6.8% net margin (TTM) · excl. goodwill write-downs -3.2% 
Negative free cash flow 
Trails peers (2/9) 
Narrow moat 17/100
Thin data 
Estimate
Watch NeoGenomics Inc for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$52.52 $4.84 Fair Value $13.28 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $4.84 – $52.52 · fair‑value band $9.96 – $16.60 · the $15.25 price screens above the $13.28 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow NeoGenomics in your weekly email

Every Wednesday you see whether NeoGenomics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.

Show moreShow less

It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains.

In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization.

The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Stock analysis

NeoGenomics Inc (NEO) currently trades at $15.25, while our estimate is $13.28, 13% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $9.96 (bear) to $16.60 (bull), the price of $15.25 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

NeoGenomics Inc reported revenue of $727M in FY2025 versus $484M in FY2021, a compound +10.7%/yr. Reported net income was −$108M in FY2025.

Key figures

Market cap $2.0B · P/S ratio 3.02 · EPS (TTM) $−0.4100 · Net margin −6.8% · Return on equity −6.3% · Return on assets (EBIT) −6.5% (5-year average) · Operating margin −4.8% · Revenue (TTM) $766M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 17 out of 100 (medium confidence).

What moves the price

The share trades about 23% below its 52-week high and 112% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −13%, NEO screens richer than that median.

Fair Value

Bear $9.96 Fair Value $13.28 Bull $16.60
Price $15.25 · Downside -12.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 44/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 14
How much profit the company makes from its sales and capital
Quality Growth 34
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 73
Debt, balance sheet and risk of trouble
Investment 97
Does it invest with discipline instead of growing at any price?
Low Volatility 8
How calm the share price moves, does not count
Price momentum 81
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 78
Distance to the 52-week high, does not count
New shares 64
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors sold shares worth $440,224 and none bought.

  • SaleGreg D AunanChief Accounting Officer20,000 shares at $16.07$321,400Aug 4, 2026
  • SaleLynn A. TetraultDirector2× since Jun 9, 2026: 10,614 shares, avg. $11.20$118,824Jun 15, 202610b5-1 plan
  • SaleWarren StonePres & Chief Operating Officer22,128 shares at $12.50$276,600Jan 20, 202610b5-1 plan
  • SaleAlicia C OlivoEVP, GC & Business Development20,916 shares at $12.00$250,992Nov 25, 202510b5-1 plan

Plus 11 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 17, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+10.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.4%
Start year 2020 (pandemic). Over 10 years: +22.0% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+37.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3.1% (2020) → −9.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

NEO screens overvalued: fair value 13% below the price. Compare with Thermo Fisher Scientific Inc →

Compare NeoGenomics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 151 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 44 · Below median
Fair Value upside −12.9% · Above median
Profitability
Return on assets −7.9% · Below median
Net margin (12 months) −6.8% · Below median
Operating margin (12 months) −4.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) 11.2% · Above median
Balance sheet
Debt / equity 0.41× · Above median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

PEG 2.09× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)16 · sector 16
FUTURE (revenue growth)56 · sector 40
PAST (return on equity)0 · sector 9
HEALTH (low debt)80 · sector 95
DIVIDEND (yield)0 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
IQVIA Holdings IQV $257.60 $291.63 +13% vs NEO
WuXi AppTec Co 603259 ¥146.07 ¥164.66 +13% vs NEO
Illumina, Inc ILMN $202.61 $227.71 +12% vs NEO
Thermo Fisher Scientific Inc TMO $686.79 $686.04 +0% vs NEO
Danaher Corporation DHR $225.77 $209.18 −7% vs NEO
IDEXX Laboratories, Inc IDXX $690.24 $496.48 −28% vs NEO
Lonza Group LONN CHF 663.00 CHF 259.80 −61% vs NEO
Mettler-Toledo International Inc MTD $1,713 $655.06 −62% vs NEO
Agilent Technologies, Inc A $172.22 $64.20 −63% vs NEO
Waters Corporation WAT $449.78 $91.26 −80% vs NEO

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

NeoGenomics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "NeoGenomics Inc Fair Value". https://www.fairvalue-calculator.com/stock/NEO

Frequently asked questions

Is NeoGenomics Inc (NEO) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $13.28 versus a price of $15.25, about 13% lower (overvalued).
What is the fair value of NEO?
Our estimate for NeoGenomics Inc is $13.28 (as of Nov 17, 2026), built from audited fundamentals. The current price: $15.25.
What is the quality score of NEO?
NeoGenomics Inc has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NeoGenomics Inc (NEO)?
Our calculated price target is the estimate of $13.28 (as of Nov 17, 2026). Cautious scenario $9.96, optimistic scenario $16.60. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the NeoGenomics Inc stock forecast for 2026?
Our estimate puts fair value at $13.28, about 13% lower versus a price of $15.25 (overvalued). Cautious scenario $9.96, optimistic scenario $16.60. The calculation is refreshed regularly with new filings.
What is the revenue of NeoGenomics Inc (NEO)?
NeoGenomics Inc reported trailing-twelve-month revenue of about $766M (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of NeoGenomics Inc (NEO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NeoGenomics Inc it is $13.28 per share (as of Nov 17, 2026), against a price of $15.25.
Is NeoGenomics Inc stock overvalued or undervalued in 2026?
As of Nov 17, 2026, NEO trades above its calculated fair value: price $15.25, fair value $13.28, a gap of about −13% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NEO?
No. The price is what the market pays today ($15.25); the fair value is what the company's own numbers justify ($13.28). For NeoGenomics Inc the two are $1.97 per share apart. That gap is exactly why we show both numbers side by side.
How much is NeoGenomics Inc worth?
The market values NeoGenomics Inc at about $2.0B (market capitalisation, as of Nov 17, 2026). Per share that is $15.25; our models calculate a fair value of $13.28 per share.
What do the bullish and bearish scenarios say about NEO?
Our models span a range for NeoGenomics Inc: cautious scenario $9.96, base $13.28, optimistic $16.60 per share (as of Nov 17, 2026, price $15.25). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of NEO?
The PEG ratio of NeoGenomics Inc is 2.09 (P/E divided by earnings growth, as of Nov 17, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of NeoGenomics Inc (NEO)?
Balance-sheet figures for NeoGenomics Inc (as of Nov 17, 2026): return on equity −6.3%, debt of 0.41 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is NEO from its 52-week high?
NeoGenomics Inc trades at $15.25, about 23% below its 52-week high of $19.91 and 112% above the low of $7.19 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of $13.28 is for.
Which stocks are comparable to NeoGenomics Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NeoGenomics Inc stock attractive at the current price?
The data as of Nov 17, 2026: price $15.25, calculated fair value $13.28 (−13%), Quality Score 44/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3% above its aggregate fair value. NeoGenomics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NeoGenomics Inc (NEO)?
The closing price on Nov 17, 2026 was $15.25. Our estimate is $13.28, about 13% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NeoGenomics Inc right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of NeoGenomics Inc

How large is the market capitalisation of NeoGenomics Inc (NEO)?
The market capitalisation of NeoGenomics Inc is $2.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NeoGenomics Inc (NEO)?
The price-to-sales ratio of NeoGenomics Inc is 3.02 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of NeoGenomics Inc (NEO)?
Earnings per share at NeoGenomics Inc are $−0.4100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of NeoGenomics Inc (NEO)?
The net margin of NeoGenomics Inc is −6.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NeoGenomics Inc (NEO)?
The return on equity (ROE) of NeoGenomics Inc is −6.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NeoGenomics Inc (NEO)?
On an EBIT basis the return on assets of NeoGenomics Inc is −6.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NeoGenomics Inc (NEO)?
The operating margin of NeoGenomics Inc is −4.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NeoGenomics Inc (NEO)?
Revenue at NeoGenomics Inc is growing 11.2% versus a year earlier (3y avg +12.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at NeoGenomics Inc (NEO)?
Earnings per share at NeoGenomics Inc are growing 131% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does NeoGenomics Inc (NEO) generate?
The free cash flow of NeoGenomics Inc is −$21.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does NeoGenomics Inc (NEO) carry?
The net debt of NeoGenomics Inc is $313M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch NeoGenomics Inc in the live analysis

One click puts NeoGenomics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.